Ziopharm granted Solasia exclusive development and commercialization rights to IV and oral darinaparsin in 13 Asia-Pacific territories

Ziopharm Oncology Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Solasia Pharma K.K.

Japan / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced